Vertex Pharmaceuticals' Kalydeco, or ivacaftor, has been approved by the FDA to cover 23 new disease-causing mutations in patients with cystic fibrosis based on data from an in-vitro cell study. The updated label indicates Kalydeco as a treatment for patients at least 2 years old with any of 33 mutations of the CF transmembrane conductance regulator gene who are responsive to the drug.
Vertex's cystic fibrosis drug gets expanded indication
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.